Top-News

DAIICHI SANKYO S/ADR News

Aktie
WKN:  ISIN:  US23381D1028 US-Symbol:  DSNKY
35,27 $
+1,57 $
+4,66%
18:32:11 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
-
Marktkapitalisierung *
-
Streubesitz
-
Index-Zugehörigkeit
-

DAIICHI SANKYO S/ADR News

21.12.22 - PR Newswire
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging PR Newswire
20.08.20 - PR Newswire
ETNA-AF-Europe Registry Data on LIXIANA®▼(edoxaban) Published in a Leading Cardiology Journal Highlights Important Clinical Considerations for Treating Ageing Patients with Atrial Fibrillation
ETNA-​AF-Europe Registry Data on LIXIANA®▼(edoxaban) Published in a Leading Cardiology Journal Highlights Important Clinical Considerations for Treating Ageing Patients with ...
18.12.19 - PR Newswire
Large Real-World Data Confirm Safety and Effectiveness of LIXIANA®▼ (edoxaban) in Routine Clinical Practice for Elderly AF Patients with Comorbidities
Large Real-​World Data Confirm Safety and Effectiveness of LIXIANA®▼ (edoxaban) in Routine Clinical Practice for Elderly AF Patients with Comorbidities PR Newswire
04.09.19 - PR Newswire
Daiichi Sankyo Presents Positive Results of the ENTRUST-AF PCI Study of LIXIANA®▼ (edoxaban) in Patients with Atrial Fibrillation
Daiichi Sankyo Presents Positive Results of the ENTRUST-​AF PCI Study of LIXIANA®▼ (edoxaban) in Patients with Atrial Fibrillation PR Newswire
19.03.19 - PR Newswire
CLEAR Wisdom Demonstrated First-in-class, Oral, Once-daily, ACL Inhibitor Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP
CLEAR Wisdom Demonstrated First-​in-class, Oral, Once-​daily, ACL Inhibitor Bempedoic Acid Significantly Lowered LDL-​Cholesterol and Reduced hsCRP PR Newswire
18.03.19 - PR Newswire
Daiichi Sankyo Presents Positive Results of the First Randomised, Controlled Trial of Uninterrupted Oral, Once-daily LIXIANA®▼ (edoxaban) in Atrial Fibrillation Patients Undergoing Catheter Ablation
Daiichi Sankyo Presents Positive Results of the First Randomised, Controlled Trial of Uninterrupted Oral, Once-​daily LIXIANA®▼ (edoxaban) in Atrial Fibrillation Patients Undergoing ...
07.01.19 - PR Newswire
Daiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet
Daiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet PR Newswire
19.11.18 - PR Newswire
Daiichi Sankyo Presentation Now Available for On-Demand Viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference
Daiichi Sankyo Presentation Now Available for On-Demand Viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference PR Newswire
08.11.18 - PR Newswire
Daiichi Sankyo to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on November 15, 2018
Daiichi Sankyo to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on November 15, 2018 Company invites individual and institutional investors, as well as ...
06.11.18 - PR Newswire
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 14th and 15th, 2018
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 14th and 15th, 2018 PR Newswire
06.08.18 - PR Newswire
New Analysis Identifies Patient Populations With Cancer-associated VTE Who Could Benefit From Treatment With Oral, Once-daily LIXIANA®▼ (edoxaban)
New Analysis Identifies Patient Populations With Cancer-​associated VTE Who Could Benefit From Treatment With Oral, Once-​daily LIXIANA®▼ (edoxaban) PR Newswire
06.08.18 - PR Newswire
New Analysis Identifies Patient Populations With Cancer-associated VTE Who Could Benefit From Treatment With Oral, Once-daily LIXIANA®▼ (edoxaban)
New Analysis Identifies Patient Populations With Cancer-​associated VTE Who Could Benefit From Treatment With Oral, Once-​daily LIXIANA®▼ (edoxaban) PR Newswire
18.05.18 - PR Newswire
LIXIANA® ▼ (edoxaban) Shows Reduced Rate of a Variety of Types of Intracranial Haemorrhage Compared to Warfarin in New Sub-analysis Presented at the European Stroke Organisation Conference 2018
LIXIANA® ▼ (edoxaban) Shows Reduced Rate of a Variety of Types of Intracranial Haemorrhage Compared to Warfarin in New Sub-​analysis Presented at the European Stroke ...
20.11.17 - PR Newswire
Daiichi Sankyo webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference
Daiichi Sankyo webcast presentation now available for on-demand viewing: dbVIC - Deutsche Bank ADR Virtual Investor Conference PR Newswire
13.11.17 - PR Newswire
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 15th and 16th, 2017
International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 15th and 16th, 2017 PR Newswire
13.11.17 - PR Newswire
Daiichi Sankyo to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on November 15th, 2017
Daiichi Sankyo to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on November 15th, 2017 PR Newswire
31.08.17 - PR Newswire
Daiichi Sankyo Terminates Development and Commercialization Agreement with Charleston Laboratories Regarding Hydrocodone Products in the U.S., including CL-108
Daiichi Sankyo Terminates Development and Commercialization Agreement with Charleston Laboratories Regarding Hydrocodone Products in the U.S., including CL-108 PR ...
29.08.17 - PR Newswire
New Sub-analysis Data Highlights the Benefit of LIXIANA®▼ (edoxaban) Over Warfarin in NVAF Patients According to More Comprehensive Stroke Risk Scoring
New Sub-​analysis Data Highlights the Benefit of LIXIANA®▼ (edoxaban) Over Warfarin in NVAF Patients According to More Comprehensive Stroke Risk Scoring PR Newswire
29.08.17 - PR Newswire
New Sub-analysis Data Highlights the Benefit of LIXIANA®▼ (edoxaban) Over Warfarin in NVAF Patients According to More Comprehensive Stroke Risk Scoring
New Sub-​analysis Data Highlights the Benefit of LIXIANA®▼ (edoxaban) Over Warfarin in NVAF Patients According to More Comprehensive Stroke Risk Scoring PR Newswire
29.08.17 - PR Newswire
New Sub-analysis Data Highlights the Benefit of LIXIANA®▼ (edoxaban) Over Warfarin in NVAF Patients According to More Comprehensive Stroke Risk Scoring
New Sub-​analysis Data Highlights the Benefit of LIXIANA®▼ (edoxaban) Over Warfarin in NVAF Patients According to More Comprehensive Stroke Risk Scoring PR Newswire

Newssuche

Videos

newspaper
30.04.24 +12,97%
Technical Trading: Sojabohnen Long bis Juli
Sojabohnen Long Typ: Turbo Open End WKN: VX41AH Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »